Enhanced oral bioavailability of piroxicam in rats by hyaluronate microspheres

Drug Development and Industrial Pharmacy

Volumn 33, Issue 4, 2007, Pages 485-491

  Piao, Ming Guan ^a   Kim, Jeong Hoon ^b   Kim, Jong Oh ^b   Lyoo, Won Seok ^a   Lee, Mann Hyung ^c   Yong, Chul Soon ^a   Choi, Han Gon ^a  

^a Yeungnam University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

^c Catholic University of Daegu   (South Korea)

Author keywords

Bbioavailability; Dissolution; Microspheres; Piroxicam; Polyethylene glycol; Sodium hyaluronate

Indexed keywords

HYALURONIC ACID; MACROGOL 4000; MICROSPHERE; PIROXICAM; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SOLUBILITY; GEOMETRY; MALE; MICROCAPSULE; NONHUMAN; PHYSICAL CHEMISTRY; POWDER; RAT; SPRAY DRYING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; HYALURONIC ACID; MALE; MICROSPHERES; PARTICLE SIZE; PIROXICAM; POLYETHYLENE GLYCOLS; POWDERS; RATS; RATS, WISTAR; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 34249305855     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600865223     Document Type: Article

References (34)

1. Alkrad, J. A., Mrestani, Y., & Neubert, R. H. (2003). The release profiles of intact and enzymatically digested hyaluronic acid from semisolid formulations using multi-layer membrane system. Eur. J. Pharm. Biopharm., 56(1), 37-41.
2. Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420.
3. Attama, A. A., & Mpamaugo, V. E. (2006). Pharmacodynamics of piroxicam from self-emulsifying lipospheres formulated with homolipids extracted from Capra hircus. Drug Deliv., 13(2), 133-137.
4. Barzegar-Jalali, M., Maleki, N., Garjani, A., Khandar, A. A., Haji-Hosseinloo, M., Jabbari, R., & Dastmalchi, S. (2002). Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. Drug Dev. Ind. Pharm., 28(6), 681-686.
5. Bhattacharyya, M., Basu, S. K., Gupta, B. K., Ghosal, S. K., Mandal, S. C., & Chattaraj, S. C. (1993). Formulation and in vitro-in vivo characterization of solid dispersions of piroxicam. Drug Dev. Ind. Pharm., 19, 29-35.
6. Cleland, J. L., & Jones, A. J. (1996). Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm. Res., 13(10), 1464-1475.
7. Dadashzadeh, S., Vali, A. M., & Rezagholi, N. (2002). LC determination of piroxicam in human plasma. J. Pharmaceut. Biomed., 28, 1201-1204.
8. Fernández, M., Margarit, M. V., Rodríguez, I. C., & Crezo, A. (1993). Dissolution kinetics of piroxicam in solid dispersions with polyethylene glycol 4000. Int. J. Pharm., 98, 29-35.
9. Fernandez-Carballido, A., Herrero-Vanrell, R., Molina-Martinez, I. T., & Pastoriza, P., (2004). Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. Int. J. Pharm., 279, 33-41.
10. Fraser, J. R. E., Laurent, T. C., & Laurent, U. B. G. (1997). Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med., 242, 27-33.
11. Goa, K. L., & Benfield, P. (1994). Hyaluronic acid - a review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound-healing. Drugs, 47(3), 536-566.
12. Jederstrom, G., Andersson, A., Grasjo, J., & Sjoholm, I. (2004). Formulating insulin for oral administration: preparation of hyaluronaninsulin complex. Pharm. Res., 21, (11), 2040-2047.
13. Jiang, H., Wang, Y., Huang, Q., Li, Y., Xu, C., Zhu, K., & Chen, W. (2005). Biodegradable hyaluronic acid/n-carboxyethyl chitosan/ protein ternary complexes as implantable carriers for controlled protein release. Macromol. Biosci., 5(12), 1226-1233.
14. Jiang, W., & Schwendeman, S. P. (2001). Stabilization and controlled release of bovine serum albumin encapsulated in poly (D, L-lactide) and poly (ethylene glycol) microsphere blends. Pharm. Res., 18 (6), 878-885.
15. Jouon, N., Rinaudo, M., Milas, M., & Desbrieres, J. (1995). Hydration of hyaluronic-acid as a function of the counterion type and relativehumidity. Carbohydrate Polym., 26(1), 69-73.
16. Jug, M., & Becirevic-Lacan, M. (2004). Influence of hydroxypropyl-β-cyclodextrin complexation on piroxicam release from buccoadhesive tablets. Eur. J. Pharm. Sci., 21, 251-260.
17. Jug, M., Becirevic-Lacan, M., Cetina-Cizmek, B., & Horvat, M. (2004). Hydroxypropyl methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-β-cyclodextrin inclusion complex. Pharmazie, 59(9), 686-691.
18. Kim, C. K., Choi, J. Y., Yoon, Y. S., Gong, J. P., Choi, H. G., Kong, J. Y., & Lee, B. J. (1994). Preparation and evaluation of dry elixir for the enhancement of dissolution rate of poorly water-soluble drugs. Int. J. Pharm., 106, 25-32.
19. Kim, C. K., Yoon, Y. S., & Kong, J. Y. (1995). Preparation and evaluation of flurbiprofen dry elixir as a novel dosage form using a spray-drying technique. Int. J. Pharm., 120, 21-31.
20. Kimura, E., Bersani-Amado, C. A., Sudo, L. S., Santos, S. R. J., & Oga, S. (1997). Pharmacokinetic profile of piroxicam b-cyclodextrin in rat plasma and lymph, Gen. Pharmacol., 28, 695-698.
21. Lapcik, L., De Smedt, S., Demeester, J., & Chabrecek, P. (1998). Hyaluronan: Preparation, structure, properties, and applications. Chem. Rev., 98(8), 2663-2684.
22. Laurent, T. C., Laurent, U. B. G., & Fraser, J. R. E. (1995). Functions of hyaluronan. Ann. Rheum. Dis., 54, 429-432.
23. Lee, S. W., Kim, M. H., & Kim, C. K. (1999). Encapsulation of ethanol by spray drying technique: effects of sodium lauryl sulfate. Int. J. Pharm., 187, 193-198.
24. Mallarde, D., Boutignon, F., Moine, F., Barre, E., David, S., Touchet, H., Ferruti, P., & Deghenghi, R. (2003). PLGA-PEG microspheres of teverelix: influence of polymer type on microsphere characteristics and on teverelix in vitro release. Int. J. Pharm., 261, 69-80.
25. Pan, R. N., Chen, J. H., & Chen, R. R. (2000). Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems. Drug Dev. Ind. Pharm., 26(9), 989-994.
26. Pollauf, E. J., Kim, K. K., & Pack, D. W. (2005). Small-molecule release from poly(D,L-lactide)/poly(D,L-lactide-co-glycolide) composite microparticles. J. Pharm. Sci., 94(9), 2013-2022.
27. Sallmann, A. R. (1985). The history of diclofenac. Semin. Arthritis Rheum., 15, 57-60.
28. Shin, S. C., & Cho, C. W. (1997). Physicochemical characterizations of piroxicam-poloxamer solid dispersion. Pharm. Dev. Technol., 2(4), 403-407.
29. Society of Toxicology (SOT) (1999). Guilding Priciples in the Use of Animals in Toxicology, www.toxicology.org/AI/FA/guidingprinciples. pdf.
30. Tagliati, C. A., Kimura, E., Nothenberg, M. S., Santos, S. R. J. C., & Oga, S. (1999). Pharmacokinetic profile and adverse gastric effect of zincpiroxicam in rats. Gen. Pharmacol., 13, 67-71.
31. Tantishaiyakul, V., Kaewnopparat, N., & Ingkatawornwong, S. (1999). Properties of solid dispersions of piroxicam in polyvinylpyrrolidones. Int. J. Pharm., 181, 143-151.
32. Turley, E. A., & Roth, S. (1980). Interactions between the carbohydrate chains of hyaluronate and chondroitin sulphate. Nature, 283(5744), 268-271.
33. Verma, M. M., Kumar, M. T., Balasubramaniam, J., & Pandit, J. K. (2003). Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations. Boll. Chim. Farm., 142(3), 119-124.
34. Yuksel, N., Karatas, A., Ozkan, Y., Savaser, A., Ozkan, S. A., & Baykara, T. (2003). Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm., 56, 453-459.